Literature DB >> 31320385

The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.

Sebastián Morán1, Maria Eréndira Calleja-Cervantes1, Jorge Gómez-Miragaya1, Alejandro Collado-Sole1, Laia Paré2, Antonio Gómez1, Violeta Serra3, Lacey E Dobrolecki4, Michael T Lewis4, Angel Diaz-Lagares1,5, Pilar Eroles6, Aleix Prat2, Manel Esteller1,7,8,9, Eva González-Suárez10.   

Abstract

Taxanes are standard therapy in clinical practice for metastatic breast cancer; however, primary or acquired chemoresistance are a common cause of mortality. Breast cancer patient-derived xenografts (PDX) are powerful tools for the study of cancer biology and drug treatment response. Specific DNA methylation patterns have been associated to different breast cancer subtypes but its association with chemoresistance remains unstudied. Aiming to elucidate docetaxel resistance mechanisms, we performed genome-wide DNA methylation in breast cancer PDX models, including luminal and triple-negative breast cancer (TNBC) models sensitive to docetaxel, their matched models after emergence of chemoresistance and residual disease after short-term docetaxel treatment. We found that DNA methylation profiles from breast cancer PDX models maintain the subtype-specific methylation patterns of clinical samples. Two main DNA methylation clusters were found in TNBC PDX and remain stable during the emergence of docetaxel resistance; however, some genes/pathways were differentially methylated according to docetaxel response. A DNA methylation signature of resistance able to segregate TNBC based on chemotherapy response was identified. Transcriptomic profiling of selected sensitive/resistant pairs and integrative analysis with methylation data demonstrated correlation between some differentially methylated and expressed genes in docetaxel-resistant TNBC PDX models. Multiple gene expression changes were found after the emergence of docetaxel resistance in TNBC. DNA methylation and transcriptional changes identified between docetaxel-sensitive and -resistant TNBC PDX models or residual disease may have predictive value for chemotherapy response in TNBC. IMPLICATIONS: Subtype-specific DNA methylation patterns are maintained in breast cancer PDX models. While no global methylation changes were found, we uncovered differentially DNA methylated and expressed genes/pathways associated with the emergence of docetaxel resistance in TNBC. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31320385     DOI: 10.1158/1541-7786.MCR-19-0040

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  9 in total

Review 1.  Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options.

Authors:  Jae Young So; Joyce Ohm; Stan Lipkowitz; Li Yang
Journal:  Pharmacol Ther       Date:  2022-07-21       Impact factor: 13.400

2.  MORC4 Promotes Chemoresistance of Luminal A/B Breast Cancer via STAT3-Mediated MID2 Upregulation.

Authors:  Jing Luo; Shiyan Zeng; Chao Tian
Journal:  Onco Targets Ther       Date:  2020-07-12       Impact factor: 4.147

Review 3.  Laboratory Models for Investigating Breast Cancer Therapy Resistance and Metastasis.

Authors:  Kevin Roarty; Gloria V Echeverria
Journal:  Front Oncol       Date:  2021-03-10       Impact factor: 6.244

Review 4.  Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer.

Authors:  Wenxiao Jiang; Guiqing Cai; Peter Hu; Yue Wang
Journal:  Acta Pharm Sin B       Date:  2021-02-10       Impact factor: 11.413

5.  Identification of a DNA Methylation-Driven Genes-Based Prognostic Model and Drug Targets in Breast Cancer: In silico Screening of Therapeutic Compounds and in vitro Characterization.

Authors:  Saisai Tian; Lu Fu; Jinbo Zhang; Jia Xu; Li Yuan; Jiangjiang Qin; Weidong Zhang
Journal:  Front Immunol       Date:  2021-10-20       Impact factor: 7.561

6.  Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells.

Authors:  Le-le Zhang; Jun Lu; Rui-Qi Liu; Min-Juan Hu; Yi-Ming Zhao; Sheng Tan; Shu-Yuan Wang; Bo Zhang; Wei Nie; Yu Dong; Hua Zhong; Wei Zhang; Xiao-Dong Zhao; Bao-Hui Han
Journal:  Acta Pharmacol Sin       Date:  2020-05-15       Impact factor: 6.150

7.  Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment.

Authors:  Bowen Chen; Shuyuan Zhang; Qiuyu Li; Shiting Wu; Han He; Jinbo Huang
Journal:  Biosci Rep       Date:  2020-11-27       Impact factor: 3.840

8.  Triple Isozyme Lactic Acid Dehydrogenase Inhibition in Fully Viable MDA-MB-231 Cells Induces Cytostatic Effects That Are Not Reversed by Exogenous Lactic Acid.

Authors:  Elizabeth Mazzio; Nzinga Mack; Ramesh B Badisa; Karam F A Soliman
Journal:  Biomolecules       Date:  2021-11-24

9.  Single-Cell Image-Based Analysis Reveals Chromatin Changes during the Acquisition of Tamoxifen Drug Resistance.

Authors:  Han Zhao; Li F Lin; Joshua Hahn; Junkai Xie; Harvey F Holman; Chongli Yuan
Journal:  Life (Basel)       Date:  2022-03-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.